



UPDATE:

Update to communications issued 20 September 2019

Medicine Supply Notification

Medroxyprogesterone (Provera®) 100mg and 200mg tablets

Tier 2 – medium impact*

Date of issue: 14/11/2019

Summary

- Pfizer, sole supplier of Provera® tablets, have advised that:
 - resupply of Provera® 100mg tablets is delayed until 13 December 2019;
 - Provera® 200mg tablets are now out of stock until 20 December 2019; and
 - Provera® 400mg tablets are available but cannot support an increase in demand.
- Unlicensed imports of medroxyprogesterone 100mg tablets remain available.

Actions Required

- For patients without sufficient supplies of Provera® tablets to last until the resolution date, prescribers may consider prescribing an unlicensed import (see supporting information below).
- If unlicensed imports are not considered suitable then patients should be referred to secondary care specialists for further management.

Supporting Information

- The following specialist importers have currently confirmed availability of unlicensed medroxyprogesterone 100mg tablets:
 - Target Healthcare Ltd
 - Mawdsleys
- Any decision to prescribe an unlicensed medicine must consider the relevant guidance and NHS Trust or local governance procedures. Please see the links below for further information.
 - [Prescribing unlicensed medicines](#), General Medical Council (GMC),
 - [The supply of unlicensed medicinal products](#), Medicines and Healthcare products Regulatory Agency (MHRA)
 - [Professional Guidance for the Procurement and Supply of Specials](#), Royal Pharmaceutical Society (RPS)

- When prescribing a product that is not licensed in the UK, prescribers must indicate on the FP10 prescription that an unlicensed product is required. This can be done by annotating the prescription with the following wording: “**special order**”.

Enquiries

If you have any queries, please contact DHSCmedicinesupplyteam@dhsc.gov.uk